Citric Acid as a Potential Prostate Cancer Biomarker Determined in Various Biological Samples

Despite numerous studies, the molecular mechanism of prostate cancer development is still unknown. Recent investigations indicated that citric acid and lipids—with a special emphasis on fatty acids, steroids and hormones (ex. prolactin)—play a significant role in prostate cancer development and progression. However, citric acid is assumed to be a potential biomarker of prostate cancer, due to which, the diagnosis at an early stage of the disease could be possible. For this reason, the main goal of this study is to determine the citric acid concentration in three different matrices. To the best of our knowledge, this is the first time for citric acid to be determined in three different matrices (tissue, urine and blood). Samples were collected from patients diagnosed with prostate cancer and from a selected control group (individuals with benign prostatic hyperplasia). The analyses were performed using the rapid fluorometric test. The obtained results were correlated with both the histopathological data (the Gleason scale as well as the Classification of Malignant Tumors (pTNM) staging scale) and the biochemical data (the values of the following factors: prostate specific antigen, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, triglyceride, total cholesterol, creatinine and prolactin) using chemometric methods. For tissue samples, the results indicated a decreased level of citric acid in the case of prostate cancer. The analyte average concentrations in serum and urine appeared to be corresponding and superior in the positive cohort. This trend was statistically significant in the case of urinary citric acid. Moreover, a significant negative correlation was demonstrated between the concentration of citric acid and the tumor stage. A negative correlation between the total cholesterol and high-density lipoprotein and prolactin was particularly prominent in cancer cases. Conversely, a negative association between low-density lipoprotein and prolactin levels was observed solely in the control group. On the basis of the results, one may assume the influence of hormones, particularly prolactin, on the development of prostate cancer. The present research allowed us to verify the possibility of using citric acid as a potential biomarker for prostate cancer.

[1]  G. Carrieri,et al.  Prostate Cancer Radiogenomics—From Imaging to Molecular Characterization , 2021, International journal of molecular sciences.

[2]  Zemin Hou,et al.  Androgens in prostate cancer: A tale that never ends. , 2021, Cancer letters.

[3]  R. Tauler,et al.  Untargeted metabolomics of prostate cancer zwitterionic and positively charged compounds in urine. , 2021, Analytica chimica acta.

[4]  M. Cooperberg,et al.  Biomarkers in Prostate Cancer Diagnosis: From Current Knowledge to the Role of Metabolomics and Exosomes , 2021, International journal of molecular sciences.

[5]  M. Matuszewski,et al.  Lipidomics as a Diagnostic Tool for Prostate Cancer , 2021, Cancers.

[6]  S. Zappavigna,et al.  Assessment of Total, PTEN-, and AR-V7+ Circulating Tumor Cell Count by Flow Cytometry in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Enzalutamide. , 2021, Clinical genitourinary cancer.

[7]  M. Markuszewski,et al.  The potential role of fatty acids in prostate cancer determined by GC-MS analysis of formalin-fixed paraffin-embedded tissue samples. , 2021, Journal of pharmaceutical and biomedical analysis.

[8]  A. Sciarra,et al.  Tissue Expression of Androgen Receptor Splice Variant 7 at Radical Prostatectomy Predicts Risk of Progression in Untreated Nonmetastatic Prostate Cancer , 2021, Oncology.

[9]  Jea-Hyun Baek,et al.  Tricarboxylic Acid (TCA) Cycle Intermediates: Regulators of Immune Responses , 2020, Life.

[10]  B. Chung,et al.  Prospective assessment of two-gene urinary test with multiparametric magnetic resonance imaging of the prostate for men undergoing primary prostate biopsy , 2020, World Journal of Urology.

[11]  David A. Bader,et al.  Tumour metabolism and its unique properties in prostate adenocarcinoma , 2020, Nature Reviews Urology.

[12]  G. Pierantoni,et al.  Effects of Long-Term Citrate Treatment in the PC3 Prostate Cancer Cell Line , 2019, International journal of molecular sciences.

[13]  L. Porter,et al.  Transcriptomics Signature from Next-Generation Sequencing Data Reveals New Transcriptomic Biomarkers Related to Prostate Cancer , 2019, Cancer informatics.

[14]  L. O’Neill,et al.  A Role for the Krebs Cycle Intermediate Citrate in Metabolic Reprogramming in Innate Immunity and Inflammation , 2018, Front. Immunol..

[15]  R. Bertolla,et al.  Prostate cancer proteomics: clinically useful protein biomarkers and future perspectives , 2018, Expert review of proteomics.

[16]  G. Andriole,et al.  Serum cholesterol and risk of high-grade prostate cancer: results from the REDUCE study , 2017, Prostate Cancer and Prostatic Diseases.

[17]  R. Mithen,et al.  Development of a LC-MS/MS Method for the Simultaneous Detection of Tricarboxylic Acid Cycle Intermediates in a Range of Biological Matrices , 2017, Journal of analytical methods in chemistry.

[18]  Z. Husain,et al.  Citrate Suppresses Tumor Growth in Multiple Models through Inhibition of Glycolysis, the Tricarboxylic Acid Cycle and the IGF-1R Pathway , 2017, Scientific Reports.

[19]  Eric Eidelman,et al.  The Metabolic Phenotype of Prostate Cancer , 2017, Front. Oncol..

[20]  J. Erikssen,et al.  Cholesterol and prostate cancer risk: a long-term prospective cohort study , 2016, BMC Cancer.

[21]  L. Pengfei,et al.  Cholesterol Levels in Blood and the Risk of Prostate Cancer: A Meta-analysis of 14 Prospective Studies , 2015, Cancer Epidemiology, Biomarkers & Prevention.

[22]  M. Hediger,et al.  Zinc transporters in prostate cancer. , 2013, Molecular aspects of medicine.

[23]  Charles Pound,et al.  Identification of Plasma Lipid Biomarkers for Prostate Cancer by Lipidomics and Bioinformatics , 2012, PloS one.

[24]  Vincent Goffin,et al.  Prolactin regulation of the prostate gland: a female player in a male game , 2011, Nature Reviews Urology.

[25]  P. Stattin,et al.  1H HRMAS NMR Derived Bio-markers Related to Tumor Grade, Tumor Cell Fraction, and Cell Proliferation in Prostate Tissue Samples , 2011, Biomarker insights.

[26]  M. Djamgoz,et al.  Citrate transport in the human prostate epithelial PNT2‐C2 cell line: electrophysiological analyses , 2004, The Journal of physiology.

[27]  M. Tan,et al.  Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve , 2004, Prostate Cancer and Prostatic Diseases.

[28]  E. Riboli,et al.  Plasma prolactin and prostate cancer risk: A prospective study , 2001, International journal of cancer.

[29]  R. Franklin,et al.  The Intermediary Metabolism of the Prostate: A Key to Understanding the Pathogenesis and Progression of Prostate Malignancy , 2000, Oncology.

[30]  Bernhard O. Palsson,et al.  Cancer cell lines , 1999 .

[31]  P. Facchini,et al.  Citrate in urine determined with a new citrate lyase method. , 1995, Clinical chemistry.

[32]  A. Heerschap,et al.  In vitro proton magnetic resonance spectroscopy of four human prostate cancer cell lines , 1995, The Prostate.

[33]  J. Kavanagh Isocitric and citric acid in human prostatic and seminal fluid: Implications for prostatic metabolism and secretion , 1994, The Prostate.

[34]  J. Arunakaran,et al.  Effects of prolactin and androgens on the prostatic lipids of castrated mature bonnet monkeys , 1990, The Prostate.

[35]  J. F. Cooper,et al.  The role of citric acid in the physiology of the prostate: a preliminary report. , 1958, Transactions. American Urological Association. Western Section.

[36]  T. Mann,et al.  Secretory function of male accessory organs of reproduction in mammals. , 1951, Physiological reviews.